Medpace Holdings MEDP

NASDAQ MEDP

$611.39 -7.66 (-1.24%)

As of: Aug 27, 2026 · 3:59 PM EDT

Key Stats

Market Cap17.20 Bn

P/E35.00

P/S6.18

Div. Yield0.00

Revenue Growth (1y) (Qtr)17.24

Add ratio to table…

About

Medpace Holdings, Inc. is a leading global contract research organization that provides outsourced clinical development services to biotechnology pharmaceutical and medical device companies. The company generates revenue by offering a full suite of services that support the entire clinical development process from Phase I through IV across many therapeutic areas including oncology metabolic cardiology antiviral and anti infective and central nervous system research. It…

Investment Thesis

▲ Bull case

Revenue was 706,600,000 in Q1 FY26, reflecting a year over year increase of 26.5%. This expansion was driven by robust demand for clinical trial services across oncology cardiovascular and metabolic therapeutic areas. Ending backlog stood at 2,900,000,000, up 2.9% from the prior year, indicating a growing reservoir of future work. Approximately 1,940,000,000 of that backlog is expected to convert to revenue over the next twelve months, providing clear visibility into near term top line performance.
Management disclosed that it is implementing targeted initiatives to improve win rate without revealing specifics to competitors. These efforts include enhancing client engagement processes and refining therapeutic area expertise to capture a larger share of incoming RFPs. Early signs show a stable win rate in Q1 despite higher cancellation pressure, suggesting the initiatives may already be taking hold. Combined with a growing pre backlog of authorized projects, the company expects conversion rates to improve and gross bookings to rise over the coming quarters.
The company generated 151,800,000 in cash flow from operating activities during Q1 FY26. Net days sales outstanding were negative 58.8 days, reflecting efficient working capital management and early receipt of customer payments. Cash and equivalents totaled 652,700,000 at quarter end, giving ample liquidity to fund organic growth initiatives and potential strategic investments. This strong cash position reduces reliance on external financing and supports continued hiring and capacity expansion despite near term booking volatility.
Medpace maintains a diversified client base with the top five customers representing roughly 28% of last twelve months revenue and the top ten at about 37%, limiting concentration risk. The firm’s focus on full service internal expertise and efficient clinical development processes creates a competitive barrier that is difficult for large pharma oriented CROs to replicate. Although AI investments are expected to be net cost intensive in the near term, the company anticipates that these expenditures will yield operational efficiencies and cost savings beyond the next two years, positioning it for improved margins later. The metabolic therapeutic area, which includes GLP 1 related work, continues to exhibit historically low cancellation rates, providing a stable revenue stream even as other segments experience volatility.

Revenue was 706,600,000 in Q1 FY26, reflecting a year over year increase of 26.5%. This expansion was driven by robust demand for clinical trial services across oncology cardiovascular and metabolic therapeutic areas. Ending backlog stood at 2,900,000,000, up 2.9% from the prior year, indicating a growing reservoir of future work. Approximately 1,940,000,000 of that backlog is expected to convert to revenue over the next twelve months, providing clear visibility into near term top line performance.
Management disclosed that it is implementing targeted initiatives to improve win rate without revealing specifics to competitors. These efforts include enhancing client engagement processes and refining therapeutic area expertise to capture a larger share of incoming RFPs. Early signs show a stable win rate in Q1 despite higher cancellation pressure, suggesting the initiatives may already be taking hold. Combined with a growing pre backlog of authorized projects, the company expects conversion rates to improve and gross bookings to rise over the coming quarters.
The company generated 151,800,000 in cash flow from operating activities during Q1 FY26. Net days sales outstanding were negative 58.8 days, reflecting efficient working capital management and early receipt of customer payments. Cash and equivalents totaled 652,700,000 at quarter end, giving ample liquidity to fund organic growth initiatives and potential strategic investments. This strong cash position reduces reliance on external financing and supports continued hiring and capacity expansion despite near term booking volatility.
Medpace maintains a diversified client base with the top five customers representing roughly 28% of last twelve months revenue and the top ten at about 37%, limiting concentration risk. The firm’s focus on full service internal expertise and efficient clinical development processes creates a competitive barrier that is difficult for large pharma oriented CROs to replicate. Although AI investments are expected to be net cost intensive in the near term, the company anticipates that these expenditures will yield operational efficiencies and cost savings beyond the next two years, positioning it for improved margins later. The metabolic therapeutic area, which includes GLP 1 related work, continues to exhibit historically low cancellation rates, providing a stable revenue stream even as other segments experience volatility.

▼ Bear case

Backlog cancellations reached their highest level in over a year during Q1 FY26, pushing the net book to bill ratio down to 0.88. This sub one ratio indicates that the company is recognizing revenue faster than it is replenishing backlog, creating a near term headwind to growth. Management acknowledged that cancellations were driven by typical factors such as product performance and reprioritization but were higher than historical averages across oncology and cardiovascular segments. Without a meaningful reduction in cancellation rates or a significant improvement in gross awards, sequential revenue growth is unlikely and the backlog coverage beyond one year continues to deteriorate.
A class action lawsuit has been filed alleging that Medpace misrepresented its cancellation rates and book to bill ratio in prior disclosures. The complaint cites a 16% single day stock drop following the Q4 FY25 results as evidence of investor harm stemming from alleged misleading statements. Although the company denies wrongdoing, the litigation introduces uncertainty and could lead to financial penalties, settlement costs, or increased scrutiny from regulators. The overhang of this legal action may weigh on investor sentiment and could affect the company’s ability to execute strategic initiatives or pursue acquisitions.
The company noted that request for proposal volumes were down both year over year and sequentially, signaling softer demand from biotech sponsors. While management emphasizes the quality of opportunities over raw RFP counts, a sustained decline in invitation volume could limit the pool of potential awards. Biotech funding, although described as stable over the past eight or nine months, remains susceptible to shifts in venture capital appetite and macroeconomic conditions. A contraction in external financing would directly impact the ability of clients to initiate new trials, thereby pressuring Medpace’s booking pipeline and revenue outlook.
EBITDA margin remained essentially flat at 21.1% in Q1 FY26 compared with 21.2% in the prior year period, indicating limited operating leverage despite revenue growth. The pass through component of revenue was elevated at approximately 44% in the quarter, which can dilute margin stability as these costs are reimbursed with little markup. Net income growth lagged EBITDA growth, increasing only 8.1% year over year due to a higher effective tax rate that reduced the bottom line conversion. Unless the company can shift the mix toward higher margin proprietary services or reduce the pass through share, overall profitability may remain constrained.

Backlog cancellations reached their highest level in over a year during Q1 FY26, pushing the net book to bill ratio down to 0.88. This sub one ratio indicates that the company is recognizing revenue faster than it is replenishing backlog, creating a near term headwind to growth. Management acknowledged that cancellations were driven by typical factors such as product performance and reprioritization but were higher than historical averages across oncology and cardiovascular segments. Without a meaningful reduction in cancellation rates or a significant improvement in gross awards, sequential revenue growth is unlikely and the backlog coverage beyond one year continues to deteriorate.
A class action lawsuit has been filed alleging that Medpace misrepresented its cancellation rates and book to bill ratio in prior disclosures. The complaint cites a 16% single day stock drop following the Q4 FY25 results as evidence of investor harm stemming from alleged misleading statements. Although the company denies wrongdoing, the litigation introduces uncertainty and could lead to financial penalties, settlement costs, or increased scrutiny from regulators. The overhang of this legal action may weigh on investor sentiment and could affect the company’s ability to execute strategic initiatives or pursue acquisitions.
The company noted that request for proposal volumes were down both year over year and sequentially, signaling softer demand from biotech sponsors. While management emphasizes the quality of opportunities over raw RFP counts, a sustained decline in invitation volume could limit the pool of potential awards. Biotech funding, although described as stable over the past eight or nine months, remains susceptible to shifts in venture capital appetite and macroeconomic conditions. A contraction in external financing would directly impact the ability of clients to initiate new trials, thereby pressuring Medpace’s booking pipeline and revenue outlook.
EBITDA margin remained essentially flat at 21.1% in Q1 FY26 compared with 21.2% in the prior year period, indicating limited operating leverage despite revenue growth. The pass through component of revenue was elevated at approximately 44% in the quarter, which can dilute margin stability as these costs are reimbursed with little markup. Net income growth lagged EBITDA growth, increasing only 8.1% year over year due to a higher effective tax rate that reduced the bottom line conversion. Unless the company can shift the mix toward higher margin proprietary services or reduce the pass through share, overall profitability may remain constrained.

Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Diagnostics & Research

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	TMO	Thermo Fisher Scientific Inc.	234.15 Bn	33.26	5.05	45.65 Bn
2	DHR	Danaher Corp /De/	152.10 Bn	38.12	6.06	27.97 Bn
3	NTRA	Natera, Inc.	48.48 Bn	-252.14	17.91	0.08 Bn
4	A	Agilent Technologies, Inc.	44.35 Bn	31.37	6.13	3.36 Bn
5	IQV	Iqvia Holdings Inc.	43.68 Bn	33.09	2.57	16.00 Bn
6	IDXX	Idexx Laboratories Inc /De	43.02 Bn	37.75	9.45	0.82 Bn
7	ILMN	Illumina, Inc.	34.39 Bn	41.68	7.65	1.49 Bn
8	MTD	Mettler Toledo International Inc/	28.29 Bn	31.24	6.84	2.11 Bn

Medpace Holdings MEDP

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password